FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.
Page 10 of 34
Jul 4, 2026The recent attention to hantavirus outbreaks raises urgent questions about whether the United States is building durable preparedness infrastructure or simply improvising from one infectious disease emergency to the next. Examining the lessons from hantavirus, this article explores shortcomings in public health readiness and the perennial dilemma of sustainable epidemic response.
Emily Carter
Jul 4, 2026Without transparent and detailed access to claims data, the Office of Personnel Management (OPM) cannot adequately address billing inconsistencies or assess the efficiency and fairness of healthcare spending within federal employee health plans. This issue raises substantial concerns about data access, oversight, and accountability in the administration of one of the nation’s largest employer-sponsored health programs.
Dr. Priya Nandakumar
Jul 4, 2026Medicare’s renewed proposal to lower payments for 340B drugs is the latest in a string of regulatory controversies surrounding the hotly debated program. With stakeholders divided on the financial impacts to hospitals and the accessibility of care for vulnerable populations, this move is likely to shape policy, hospital strategy, and patient access for years to come.
Dr. Priya Nandakumar
Jul 2, 2026Recent Congressional scrutiny on Eli Lilly, Pfizer, Merck, BMS, and AbbVie’s clinical research in China highlights an unresolved rift between U.S. government officials and the biopharmaceutical industry. This divide centers on whether China’s biotech expansion threatens national security or offers vital economic value, as transpacific collaborations shape the future of global drug development.
Daniel Cho
Jul 2, 2026The decision to halt Colorado’s unique attempt at drug price regulation carries significant implications for state-level legislative efforts, the pharmaceutical industry, and future court battles over pricing controls. With healthcare costs continually at the forefront of national political discourse, this case exemplifies the high stakes for states, industry, and patients.
Sophia Reynolds
Jul 1, 2026In a move that could shift the landscape of nicotine consumption and tobacco regulation, the FDA has allowed Zyn to advertise its nicotine pouches as safer than combustible cigarettes. This decision highlights ongoing debates around risk reduction and the evolving role of non-combustible nicotine products in public health strategies.
Sophia Reynolds
Jul 1, 2026In a significant move, the FDA has rejected filings from Unicycive Therapeutics and Sobi due to shortcomings found within their contract manufacturing partners. This decision highlights the ongoing challenges and regulatory scrutiny that biopharma companies face around outsourced production, especially as the demand for novel therapies in chronic disease areas continues to rise.
Daniel Cho
Jun 30, 2026The detection of Marburg virus cases in western Uganda introduces new complexities for Ebola response teams and regional public health authorities. As central Africa experiences overlapping outbreaks of dangerous viral hemorrhagic fevers, questions about surveillance, containment, resource allocation, and international coordination come to the fore.
Daniel Cho
Jun 30, 2026The FDA's move to include longevity and wellness experts on a committee that will soon advise on relaxing peptide compound restrictions is attracting both interest and concern across the biomedical landscape. This development highlights the increasingly complex intersection of wellness, regulatory oversight, and public trust.
Dr. Priya Nandakumar
Jun 30, 2026With nearly half of U.S. states launching legal action against federal Medicaid work requirements, the clash underscores the persistent divides in American health policy. The lawsuits reflect wide-ranging concerns about access to care, administrative burden, and the intersection between social welfare and labor policy.
Dr. Priya Nandakumar
Jun 30, 2026Starting July 1, alterations to federal student loan policy are having profound implications for aspiring healthcare professionals, especially women. As debate intensifies over what kinds of labor—and whose labor—receive public investment, the industry faces a reckoning over gender equity, workforce sustainability, and the future shape of care delivery.
Emily Carter
Jun 30, 2026With the exit of Vijay Kumar, the FDA’s top gene therapy regulator, the agency faces another leadership gap just as gene therapy innovation surges. This change, set against a backdrop of wider FDA shakeups, could have far-reaching implications for biopharma strategy, regulatory timelines, and patient expectations.
Sophia ReynoldsMachine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.